Navigation Links
PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
Date:3/20/2008


Strategic Acquisition Reinforces PharmAthene's Status

as a Premier Biodefense Company;

Creates Expanded Biodefense Pipeline

ANNAPOLIS, Md., and TEES VALLEY, England, March 20 /PRNewswire-FirstCall/ -- PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against biological and chemical threats, and Avecia Biologics Limited, a contract manufacturer of biopharmaceuticals, announced today that the companies have entered into a definitive sale and purchase agreement under which PharmAthene will acquire all of the assets and intellectual property related to Avecia's biodefense vaccines business. This includes a second generation recombinant Protective Antigen (rPA) anthrax vaccine, a recombinant dual antigen plague vaccine, and a third generation rPA anthrax vaccine program. As part of this agreement, PharmAthene and Avecia Biologics have entered into a long-term manufacturing contract for the supply of these vaccine drug substances to PharmAthene.

David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "Our acquisition of Avecia's biodefense vaccine assets significantly advances PharmAthene's strategy of building a leading biodefense company with a comprehensive portfolio of medical countermeasures that specifically meet the requirements for procurement established by the United States Government. Importantly, the rPA anthrax vaccine presents a promising near-term procurement opportunity for PharmAthene based upon a recently issued government solicitation outlining requirements to procure 25 million doses of an rPA vaccine."

Eric I. Richman, PharmAthene's Senior Vice President of Business Development & Strategic Planning commented, "Our two companies have a proven track record in successfully collaborating with the U.S. and U.K. Governments in the development of biodefense medical counter
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
2. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
3. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
4. PharmAthene to Present at the BIO CEO & Investor Conference 2008
5. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
6. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
7. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
10. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
11. Corgenix Signs Technology Licensing Agreement With Japanese Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Dr. Gerald Zon ... acid research, recently launched a new blog in conjunction ... ( zon.trilinkbiotech.com ), focuses on what,s trending in the ... industry thought leaders, discussions of research presented at conferences ... Dr. Zon (PhD Princeton University 1971) developed ...
(Date:5/20/2013)... Md. and BALTIMORE , May 20, ... a regional private-public partnership focusing on commercializing market-relevant ... in Central Maryland , today ... as the first Entrepreneur-in-Residence (EIR) for BHI at ... Heart, Lung and Blood Institute (NHLBI). Dr. ...
(Date:5/20/2013)... BOSTON , May 20, 2013 Rhythm ... clinical trial of RM-131, the company,s novel ghrelin agonist ... diabetic patients. The trial demonstrated that RM-131 significantly accelerates ... in type 1 diabetic patients with diabetic gastroparesis. The ... conference in Orlando and recently ...
(Date:5/20/2013)... 2013 Recognizing exciting and innovative ... to its 2013 Class of Young Professors. ... provide this outstanding international group with more than ... science to meet global challenges.     , The DuPont ... young and untenured research faculty working in areas ...
Breaking Biology Technology:Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3
... Leaders Join Forces to Promote Early Detection ... and Treatment of Hypertension in the UK, ... Ltd. (Tel Aviv Stock Exchange: INCR), and Omron Healthcare (UK),Ltd., ... to strengthen the link between hypertension diagnostics and,therapies in the ...
... Blood found 92 percent reduction in ... incidence ... a rare,blood disorder called PNH experienced a 92 percent reduction ... (eculizumab), according to an analysis of clinical studies,recently published online ...
... 20 - Essential, Structure-Searchable Chemistry ... to Researchers Elsevier Information Systems GmbH, ... of scientific, technical and medical information,is pleased ... the CrossFire Beilstein,database will contain more than ...
Cached Biology Technology:InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 2InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 3InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8CrossFire Beilstein Database Exceeds Ten Million Compounds 2CrossFire Beilstein Database Exceeds Ten Million Compounds 3
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
(Date:5/20/2013)... Science Foundation (NSF) planning grant will help establish the ... program of the University of Illinois at Urbana-Champaign and ... will be devoted to research in drying moist, porous ... and paper products; chemical products; textiles; and biopharmaceuticals," said ... science and human nutrition and the Illinois site director. ...
(Date:5/19/2013)... a strain of electricity-producing bacteria that can grow using ... dioxide as its sole source of carbon. Researchers ... at the 113th General Meeting of the American Society ... current production solely on hydrogen," says Amit Kumar, a ... are part of the Lovley Lab Group at the ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
... Fla. (June 16, 2009) To determine if guided ... and functional recovery, researchers at the University of Pittsburgh ... the injured peripheral nerves of laboratory rats. ... shown to be an abundant source of post-natal precursor ...
... engineers have taken a first step toward a minimally ... heat administered from the end of a catheter. ... possible to treat brain tumors without the side effects ... or radiation. The bioengineers designed and built an ...
... University of California, Berkeley, researchers have found what they ... of the puzzle about how stress causes sexual dysfunction ... of stress hormones - glucocorticoids such as cortisol - ... hormone (GnRH), and subsequently suppresses sperm count, ovulation and ...
Cached Biology News:Peripheral nerve repair with fat precursor cells led to wider nerves and less muscle atrophy 2Potential for non-invasive brain tumor treatment 2Stress puts double whammy on reproductive system, fertility 2Stress puts double whammy on reproductive system, fertility 3
... linear ion trap mass spectrometer enables high-throughput ... The LXQ linear ion trap mass spectrometer ... applications, delivering the fast cycle time and ... trap at an attractive price. The ...
... developed specifically for reduced mutagenicity to be ... agarose or acrylamide gels. SYBR Safe stain is ... SYBR Safe stain's detection sensitivity is better than ... as a premixed solution that can be used ...
... These are just some the things youll ... of Protein-Protein Interactions, edited by Erica Golemis, One ... skillfully edited compilation of topics in protein interaction ... text that must be a part of your ...
... This exceptionally sensitive nucleic acid gel stain ... low background in gels, making it ideal for ... standard UV transilluminators. SYBR Green I nucleic ... in capillary electrophoresis, real-time PCR assays and bandshift ...
Biology Products: